These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 14710895)

  • 1. Interleukin-2 receptor-directed therapies for cutaneous lymphomas.
    Foss FM; Waldmann TA
    Hematol Oncol Clin North Am; 2003 Dec; 17(6):1449-58. PubMed ID: 14710895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
    Foss FM
    Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
    Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
    Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous T-cell lymphoma: Biologic targets for therapy.
    Choi J; Foss F
    Curr Hematol Malig Rep; 2007 Oct; 2(4):272-7. PubMed ID: 20425380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal Antibodies.
    Geskin LJ
    Dermatol Clin; 2015 Oct; 33(4):777-86. PubMed ID: 26433849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory effects of rexinoids.
    Foss F
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S21-5. PubMed ID: 16516672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.
    Foss FM; Bacha P; Osann KE; Demierre MF; Bell T; Kuzel T
    Clin Lymphoma; 2001 Mar; 1(4):298-302. PubMed ID: 11707845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
    Duvic M
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two novel therapies for the treatment of cutaneous T-cell lymphoma.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S7. PubMed ID: 11707856
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.
    Kadin ME; Vonderheid EC
    Nat Rev Clin Oncol; 2010 Aug; 7(8):430-2. PubMed ID: 20668480
    [No Abstract]   [Full Text] [Related]  

  • 12. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date.
    Kuzel TM
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S33-6. PubMed ID: 11707861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?
    Bunn PA
    Arch Dermatol; 1995 May; 131(5):603-5. PubMed ID: 7537952
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-IL-2 receptor monoclonal antibody (anti-Tac) treatment of T-cell lymphoma.
    Waldmann TA
    Important Adv Oncol; 1994; ():131-41. PubMed ID: 8206486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
    Duvic M
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denileukin diftitox.
    Figgitt DP; Lamb HM; Goa KL
    Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choices in the treatment of cutaneous T-cell lymphoma.
    Hymes KB
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):18-23. PubMed ID: 17474355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
    Foss FM
    Clin Lymphoma; 2000 Sep; 1(2):110-6; discussion 117. PubMed ID: 11707818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
    Gorgun G; Foss F
    Blood; 2002 Aug; 100(4):1399-403. PubMed ID: 12149223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denileukin diftitox.
    Saxon M
    Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.